Patients with relapsed CML, MM, or other diseases were treated with defined doses of CD8-depleted CD4+ T cells with clinical responses in ~80% of patients and GVHD developing in about one-third of patients [compared to a ~75% GVHD incidence with conventional DLI (46)]. The gene discussed is CD8A; the disease is graft versus host disease.